Revenue rose 6.08% and net profit surged 23.19% year-over-year in the first nine months of 2024, driven by strong CHC and prescription drug growth. Strategic M&A, including a major Tasly acquisition, and robust R&D supported performance.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.